Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kangfupen for Chronic Radiation-Induced Rectal Injury
NCT07065175Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Primary completion
- Jan 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of repifermin in chronic radiation proctitis (CRP), sponsored by Peking Union Medical College Hospital. Primary endpoint: Change in LENT-SOMA rectal radiation injury scores at 3 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
repifermin
03
Conditions
chronic radiation proctitis (CRP)
Beyond the preview
Go deeper on NCT07065175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065175.